Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia
暂无分享,去创建一个
R. Schlenk | H. Döhner | J. Hasford | A. Ganser | D. Niederwieser | T. Büchner | G. Ehninger | M. Schaich | R. Krahl | J. Krauter | C. Sauerland | J. Engel | U. Creutzig | A. Schumacher | D. Messerer
[1] K. Döhner,et al. Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG. , 2006 .
[2] A. Ganser,et al. Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. , 2006 .
[3] D. Reinhardt,et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Henze,et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials , 2005, Leukemia.
[5] J. Blanch,et al. Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Andrykowski,et al. Positive and negative psychosocial sequelae of bone marrow transplantation: Implications for quality of life assessment , 1996, Journal of Behavioral Medicine.
[7] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Fayers,et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3–5 years after stem cell transplantation , 2004, Bone Marrow Transplantation.
[9] M. Watson,et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. , 2004, European journal of cancer.
[10] Jacqueline Kerr,et al. Quality of Life Following Breast‐Conserving Therapy or Mastectomy: Results of a 5‐Year Prospective Study , 2004, The breast journal.
[11] A. Ganser,et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trial , 2004, Annals of Hematology.
[12] Alberto Redaelli,et al. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. , 2004, Cancer treatment reviews.
[13] Chiun Hsu,et al. Survival-weighted health profile for long-term survivors of acute myelogenous leukemia , 2003, Quality of Life Research.
[14] M. King. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 , 1996, Quality of Life Research.
[15] J. Engel,et al. Predictors of Quality of Life of Breast Cancer Patients , 2003, Acta oncologica.
[16] L. Robison,et al. Late‐effects among survivors of leukaemia and lymphoma during childhood and adolescence , 2003, British journal of haematology.
[17] J. Engel,et al. Quality of Life in Rectal Cancer Patients: A Four-Year Prospective Study , 2003, Annals of surgery.
[18] S. Fröhling,et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.
[19] H. Dombret,et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.
[20] H. Döhner,et al. Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. , 2002, Leukemia research.
[21] P. Höcker,et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation , 2002, Bone Marrow Transplantation.
[22] B. Brennan,et al. Endocrine late effects after bone marrow transplant. , 2002, British journal of haematology.
[23] H. Dombret,et al. A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .
[24] M. Minden,et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Berdel,et al. Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia. , 2002, Leukemia research.
[26] K. Sullivan,et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. , 2001, Blood.
[27] G. Ehninger,et al. Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia , 2001, British journal of haematology.
[28] D. Fairclough,et al. Recovery after stem-cell transplantation for hematologic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Gray,et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone , 1999, Cancer.
[30] W. Hiddemann,et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.
[31] T. Büchner,et al. Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy – a longitudinal study , 1998, Leukemia.
[32] B. Craven,et al. Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year , 1998, Bone Marrow Transplantation.
[33] M. Björkholm,et al. Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation – a prospective study , 1997, Bone Marrow Transplantation.
[34] F. Mandelli,et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial , 1997, Bone Marrow Transplantation.
[35] M. Bullinger. [Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine]. , 1997, Psychotherapie, Psychosomatik, medizinische Psychologie.
[36] G. Schiller,et al. Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors. , 1996, Psychosomatics.
[37] M. Stauch,et al. Long-Term Results in Adult AML: Comparison of Postremission Chemotherapy vs. Autologous BMT vs. Allogeneic BMT , 1996 .
[38] W. Hiddemann. Acute leukemias V : experimental approaches and management of refractory disease , 1996 .
[39] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[40] K. Young,et al. Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data. , 1993, Oncology nursing forum.
[41] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[42] J. Holland,et al. Long‐term psychological adjustment of acute leukemia survivors: impact of bone marrow transplantation versus conventional chemotherapy. , 1992, Psychosomatic medicine.
[43] W. Hiddemann,et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[45] E. Freireich,et al. Treatment of acute leukemia in protected environment units , 1979, Cancer.